Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Nuclear Medicine and Biology

Volumn 37, Issue 7, 2010, Pages 785-794

  Kato, Yukinari ^a,b   Vaidyanathan, Ganesan ^a   Kaneko, Mika Kato ^a,b   Mishima, Kazuhiko ^c   Srivastava, Nidhi ^a   Chandramohan, Vidyalakshmi ^a   Pegram, Charles ^a   Keir, Stephen T ^a   Kuan, Chien Tsun ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b YAMAGATA UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biodistribution; Internalization; Malignant gliomas; Monoclonal antibody; Podoplanin; SGMIB

Indexed keywords

3 IODOBENZOIC ACID; IMMUNOGLOBULIN G2A; IODINE 125; IODINE 131; NZ 1; SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RETENTION; DRUG TARGETING; DRUG TUMOR LEVEL; FEMALE; GLIOBLASTOMA; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; RADIOIODINATION; RAT; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; IODINE RADIOISOTOPES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION;

EID: 77957003754     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.03.010     Document Type: Article

References (42)

1. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344:114-123.
2. Wong A.J., Bigner S.H., Bigner D.D., Kinzler K.W., Hamilton S.R., Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987, 84:6899-6903.
3. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55:3140-3148.
4. Wikstrand C.J., He X.M., Fuller G.N., Bigner S.H., Fredman P., Svennerholm L., et al. Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. J Neuropathol Exp Neurol 1991, 50:756-769.
5. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989, 49:2807-2813.
6. Zalutsky M.R., Moseley R.P., Benjamin J.C., Colapinto E.V., Fuller G.N., Coakham H.P., et al. Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 1990, 50:4105-4110.
7. Kato Y., Kuan C.T., Chang J., Kaneko M.K., Ayriss J., Piao H., et al. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochem Biophys Res Commun 2010, 391:750-755.
8. Kato Y., Fujita N., Kunita A., Sato S., Kaneko M., Osawa M., et al. Molecular identification of aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003, 278:51599-51605.
9. Kaneko M.K., Kato Y., Kitano T., Osawa M. Conservation of a platelet activating domain of aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006, 378:52-57.
10. Kaneko M., Kato Y., Kunita A., Fujita N., Tsuruo T., Osawa M. Functional sialylated O-glycan to platelet aggregation on aggrus (T1alpha/podoplanin) molecules expressed in Chinese hamster ovary cells. J Biol Chem 2004, 279:38838-38843.
11. Kaneko M.K., Kato Y., Kameyama A., Ito H., Kuno A., Hirabayashi J., et al. Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett 2007, 581:331-336.
12. Kato Y., Kaneko M., Sata M., Fujita N., Tsuruo T., Osawa M. Enhanced expression of aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005, 26:195-200.
13. Martin-Villar E., Scholl F.G., Gamallo C., Yurrita M.M., Munoz-Guerra M., Cruces J., et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005, 113:899-910.
14. Dumoff K.L., Chu C.S., Harris E.E., Holtz D., Xu X., Zhang P.J., et al. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006, 19:708-716.
15. Wicki A., Lehembre F., Wick N., Hantusch B., Kerjaschki D., Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006, 9:261-272.
16. Vormittag L., Thurnher D., Geleff S., Pammer J., Heiduschka G., Brunner M., et al. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy. Int J Radiat Oncol Biol Phys 2009, 73:913-918.
17. Ito T., Ishii G., Nagai K., Nagano T., Kojika M., Murata Y., et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 2009, 63:418-424.
18. Rahadiani N., Ikeda J.I., Makino T., Tian T., Qiu Y., Mamat S., Wang Y., Doki Y., Aozasa K., Morii E. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol 2010, 17:1311-1323.
19. Kato Y., Sasagawa I., Kaneko M., Osawa M., Fujita N., Tsuruo T. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004, 23:8552-8556.
20. Suzuki H., Kato Y., Kaneko M.K., Okita Y., Narimatsu H., Kato M. Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma. FEBS Lett 2008, 582:341-345.
21. Mishima K., Kato Y., Kaneko M.K., Nakazawa Y., Kunita A., Fujita N., et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl) 2006, 111:563-568.
22. Mishima K., Kato Y., Kaneko M.K., Nishikawa R., Hirose T., Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl) 2006, 111:483-488.
23. Kato Y., Kaneko M.K., Kuno A., Uchiyama N., Amano K., Chiba Y., et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006, 349:1301-1307.
24. Kunita A., Kashima T.G., Morishita Y., Fukayama M., Kato Y., Tsuruo T., et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007, 170:1337-1347.
25. Kato Y., Kaneko M.K., Kunita A., Ito H., Kameyama A., Ogasawara S., et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008, 99:54-61.
26. Martin-Villar E., Megias D., Castel S., Yurrita M.M., Vilaro S., Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial- mesenchymal transition. J Cell Sci 2006, 119:4541-4553.
27. Kawase A., Ishii G., Nagai K., Ito T., Nagano T., Murata Y., et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008, 123:1053-1059.
28. Kawaguchi H., El-Naggar A.K., Papadimitrakopoulou V., Ren H., Fan Y.H., Feng L., et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008, 26:354-360.
29. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
30. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
31. Hambardzumyan D., Squatrito M., Holland E.C. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006, 10:454-456.
32. Atsumi N., Ishii G., Kojima M., Sanada M., Fujii S., Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 2008, 373:36-41.
33. Ogasawara S., Kaneko M.K., Price J.E., Kato Y. Characterization of anti- podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 2008, 27:259-267.
34. 131I]SGMIB). Bioconjug Chem 2001, 12:428-438.
35. Zalutsky M.R., Zhao X.G., Alston K.L., Bigner D. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med 2001, 42:1508-1515.
36. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89.
37. Friedman H.S., Colvin O.M., Skapek S.X., Ludeman S.M., Elion G.B., Schold S.C., et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988, 48:4189-4195.
38. Beers R., Chowdhury P., Bigner D., Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 2000, 6:2835-2843.
39. Reist C.J., Archer G.E., Kurpad S.N., Wikstrand C.J., Vaidyanathan G., Willingham M.C., et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 1995, 55:4375-4382.
40. Saga T., Neumann R.D., Heya T., Sato J., Kinuya S., Le N., et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A 1995, 92:8999-9003.
41. 211At. Nucl Med Biol 2003, 30:351-359.
42. Vaidyanathan G., Affleck D.J., Bigner D.D., Zalutsky M.R. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 2002, 29:1-11.